April 5, 2016 – FDA requires heart failure warning on labels of Onglyza and other DPP-inhibitors.
April 2016 – FDA label requirement
Announcement Date: April 5, 2016
April 5, 2016 – FDA requires heart failure warning on labels of Onglyza and other DPP-inhibitors.